Rishi Pukhraj, Agarwal Ashutosh, Chatterjee Pritam, Sharma Tarun, Sharma Minal, Saravanan Munusamy, Ravikumar R
Shri Bhagwan Mahavir Vitreoretinal Services, Sankara Nethralya, Chennai, India.
Apollo Institute of Interventional Radiology, Apollo Hospital, Chennai, India.
Ocul Oncol Pathol. 2020 Jan;6(1):66-73. doi: 10.1159/000500010. Epub 2019 Jun 4.
There are limited reports of intra-arterial chemotherapy (IAC) for retinoblastoma (RB) from developing world.
In this study, we report our 4-year experience of IAC for RB from India.
Retrospective, interventional case series. Primary outcome measures included tumor regression, vitreous seeds and subretinal seeds control, and globe salvage. Secondary outcome measures were best-corrected visual acuity and treatment complications.
Fifteen eyes underwent 53 IAC procedures over mean 28.6 ± 13.8 months (range 10-51 months). IAC was employed as primary ( = 6) or secondary ( = 9) chemotherapy. Following IAC, complete regression of main tumor was seen in 7 eyes (47%) and partial regression in 3 (20%) eyes. Enucleation was done in 5(33%) eyes. Globe salvage rates were achieved in 1 eye (100%) in group B, 2 eyes (67%) in group C ( = 3), 6 eyes (67%) in group D ( = 9), and 1 eye (50%) in group E ( = 2). Following IAC, Kaplan-Meier survival curve showed 93% globe survival rate at 1 year, 76% at 2 years, and 66% at 3, and 4 years.
IAC has enhanced globe salvage rates in eyes with RB. Multicenter studies with longer follow-up are necessary to better understand outcomes in the long term.
来自发展中世界的关于视网膜母细胞瘤（RB）动脉内化疗（IAC）的报道有限。
在本研究中，我们报告了我们在印度进行的IAC治疗RB的4年经验。
回顾性、介入性病例系列研究。主要结局指标包括肿瘤消退、玻璃体种植和视网膜下种植的控制以及眼球挽救。次要结局指标是最佳矫正视力和治疗并发症。
15只眼在平均28.6±13.8个月（范围10 - 51个月）内接受了53次IAC治疗。IAC被用作一线（n = 6）或二线（n = 9）化疗。IAC治疗后，7只眼（47%）的主要肿瘤完全消退，3只眼（20%）部分消退。5只眼（33%）进行了眼球摘除。B组1只眼（100%）、C组（n = 3）2只眼（67%）、D组（n = 9）6只眼（67%）和E组（n = 2）1只眼（50%）实现了眼球挽救率。IAC治疗后，Kaplan-Meier生存曲线显示1年时眼球生存率为93%，2年时为76%，3年和4年时为66%。
IAC提高了RB患眼的眼球挽救率。需要进行多中心、长期随访研究以更好地了解长期结局。
